Lung Cancer Clinical Trial

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Summary

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of first dose.

Exclusion Criteria:

Untreated symptomatic central nervous system metastases or leptomeningeal metastases.
Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts.
Participants with an active, known, or suspected autoimmune disease.

Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

225

Study ID:

NCT05543629

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

START Midwest
Grand Rapids Michigan, 49546, United States More Info
Manish Sharma, Site 0005
Contact
616-600-3810
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Martin Gutierrez, Site 0003
Contact
551-996-5863
Carolina BioOncology Institute
Huntersville North Carolina, 28078, United States More Info
John Powderly, Site 0006
Contact
704-654-0485
Local Institution - 0002
Clayton Victoria, 3168, Australia More Info
Site 0002
Contact

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

225

Study ID:

NCT05543629

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.